New HIV vaccine trial aims to boost immune control in patients on ART
NCT ID NCT07530198
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an experimental HIV vaccine called ICVAX in 22 adults with HIV who are stable on antiretroviral therapy (ART). The goal is to see if the vaccine is safe and can strengthen the body's immune response against HIV. Participants receive four injections over several months and are monitored for about a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Chinese University of Hong Kong Phase 1 Clinical Trial Centre at Prince of Wales Hospital
RECRUITINGShatin, New Territories, 00000, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact